Harm Westdorp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Harm Westdorp has a total of 224 co-authors. Here are the top co-authors by number of shared publications:
- Carl Gustav Figdor
Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, the Netherlands
4 shared publications - Gerty Schreibelt
Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, the Netherlands
4 shared publications - I. Jolanda M. de Vries
Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, the Netherlands
4 shared publications - Nielka P. van Erp
Department of Pharmacy, Pharmacology and Toxicology, Radboud University Medical Center, Nijmegen, the Netherlands
3 shared publications - Niven Mehra
Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands
3 shared publications - Rutger H. T. Koornstra
Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 248
Timing of first-line palliative systemic therapy in metastatic esophagogastric adenocarcinoma: A population-based analysis & target trial emulation
- 29 September 2026
- Published by Elsevier in European Journal of Cancer
- Vol. 248
Open AccessTiming of first-line palliative systemic therapy in metastatic esophagogastric adenocarcinoma: A population-based analysis & target trial emulation
- Open Access
- 15 March 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101146
The complication sum score: A Delphi-based approach to summarize treatment related complications for esophageal cancer
- 15 March 2026
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 59, 101146
Open AccessThe complication sum score: A Delphi-based approach to summarize treatment related complications for esophageal cancer
- Open Access
- 27 January 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (2)
Effects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES study
Background: Patients with incurable gastroesophageal adenocarcinoma have an impaired health-related quality of life (HRQOL). Exercise combined with nutritional support may improve this outcome. Careful evaluation of this supportive care strategy is needed to avoid burdening patients at this vulnerable stage with interventions that may offer no (meaningful) benefit. Therefore, this study aims to investigate the effects of a combined exercise and nutritional intervention on HRQOL in patients with incurable gastroesophageal adenocarcinoma. Methods: RADICES (the effect of exeRcise And Diet on quality of life in patients with Incurable Cancer of Esophagus and Stomach) is a multicenter randomized controlled trial aiming to include 196 patients with incurable gastroesophageal adenocarcinoma. Participants are randomly assigned (1:1) to a patient-tailored intervention or a control group. The intervention group is provided with 2 training sessions per week and biweekly nutritional consultations, delivered by trained physiotherapists and dietitians, during 12 weeks. The control group receives usual care supplemented with general physical activity advice. The primary outcome is the difference in HRQOL between the intervention group and the control group at 12 weeks, accounting for baseline HRQOL, measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–30 summary score. HRQOL is assessed at baseline, 6 weeks, 12 weeks, and every 3 months thereafter up to 1 year. Key secondary outcomes include patient-reported outcomes, cardiorespiratory fitness, dietary intake, disease progression, overall survival, and cost-effectiveness. Adherence and safety are monitored throughout the intervention period. Conclusion: This study will generate evidence on the effectiveness of a patient-tailored combined exercise and nutritional intervention in patients with incurable gastroesophageal adenocarcinoma. If effective for HRQOL, this intervention could be integrated into standard care for patients with incurable gastroesophageal adenocarcinoma. Trial registration: clinicaltrials.gov NCT06138223. Date of trial registration: November 18, 2023 Date and version study protocol: 28-04-2025 version 3.1 Date start recruitment: 19-01-2024
- 27 January 2026
- Published by Oxford University Press (OUP) in JNCI Cancer Spectrum
- Vol. 10 (2)
Open AccessEffects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES study
Background: Patients with incurable gastroesophageal adenocarcinoma have an impaired health-related quality of life (HRQOL). Exercise combined with nutritional support may improve this outcome. Careful evaluation of this supportive care strategy is needed to avoid burdening patients at this vulnerable stage with interventions that may offer no (meaningful) benefit. Therefore, this study aims to investigate the effects of a combined exercise and nutritional intervention on HRQOL in patients with incurable gastroesophageal adenocarcinoma. Methods: RADICES (the effect of exeRcise And Diet on quality of life in patients with Incurable Cancer of Esophagus and Stomach) is a multicenter randomized controlled trial aiming to include 196 patients with incurable gastroesophageal adenocarcinoma. Participants are randomly assigned (1:1) to a patient-tailored intervention or a control group. The intervention group is provided with 2 training sessions per week and biweekly nutritional consultations, delivered by trained physiotherapists and dietitians, during 12 weeks. The control group receives usual care supplemented with general physical activity advice. The primary outcome is the difference in HRQOL between the intervention group and the control group at 12 weeks, accounting for baseline HRQOL, measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–30 summary score. HRQOL is assessed at baseline, 6 weeks, 12 weeks, and every 3 months thereafter up to 1 year. Key secondary outcomes include patient-reported outcomes, cardiorespiratory fitness, dietary intake, disease progression, overall survival, and cost-effectiveness. Adherence and safety are monitored throughout the intervention period. Conclusion: This study will generate evidence on the effectiveness of a patient-tailored combined exercise and nutritional intervention in patients with incurable gastroesophageal adenocarcinoma. If effective for HRQOL, this intervention could be integrated into standard care for patients with incurable gastroesophageal adenocarcinoma. Trial registration: clinicaltrials.gov NCT06138223. Date of trial registration: November 18, 2023 Date and version study protocol: 28-04-2025 version 3.1 Date start recruitment: 19-01-2024
- Open Access
- 20 May 2025
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 46, 101021
Exploring the effects of exercise on immune cell function and tumour infiltration in patients with breast cancer receiving neoadjuvant chemotherapy – a feasibility trial
- 20 May 2025
- Published by Elsevier in Brain, Behavior, & Immunity - Health
- Vol. 46, 101021
Open AccessExploring the effects of exercise on immune cell function and tumour infiltration in patients with breast cancer receiving neoadjuvant chemotherapy – a feasibility trial
- Open Access
Exploring the Effect of a Supervised Exercise Intervention on Immune Cell Function and Tumour Infiltration in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
Pre-clinical studies have shown that exercise can decrease tumour growth through mobilisation, activation, and increased tumour infiltration of natural killer (NK) and CD8 + T cells. It is currently unclear whether this can be extrapolated to patients. Therefore, a pilot study was set up to examine the feasibility of obtaining an additional study biopsy and to generate preliminary data on the potential effects of exercise on immune cell function and tumour infiltration. Twenty patients with stage I-III breast cancer receiving neoadjuvant chemotherapy were included (participation rate: 27%). Patients were randomised into the intervention group consisting of a six-week supervised aerobic and resistance exercise program or the control group. Blood samples and tumour biopsies were collected before randomisation and after six weeks of chemotherapy. For 8 of 20 (40%) patients, we were able to obtain and analyse biopsies at diagnosis and six-week follow-up. Upon co-culture of peripheral blood mononuclear cells with K562 tumour cells, the exercise group showed increased expression of the degranulation marker CD107a on NK cells (β=1038.5, 95%CI=56.9; 2020.2, p=0.04), and a trend towards increased tumour cell lysis (β=18.8%, 95%CI=-3.9; 41.5, p=0.10) compared to the control group. In conclusion, the study design was feasible with regard to the participation rate, however, revision is needed with regard to the use of a study-related biopsy. Preliminary evidence was found that exercise during chemotherapy may enhance peripheral NK cell function. Larger studies are needed to extensively study the potential effects of exercise on immune cell function and tumour infiltration in patients with cancer.
Open AccessExploring the Effect of a Supervised Exercise Intervention on Immune Cell Function and Tumour Infiltration in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
Pre-clinical studies have shown that exercise can decrease tumour growth through mobilisation, activation, and increased tumour infiltration of natural killer (NK) and CD8 + T cells. It is currently unclear whether this can be extrapolated to patients. Therefore, a pilot study was set up to examine the feasibility of obtaining an additional study biopsy and to generate preliminary data on the potential effects of exercise on immune cell function and tumour infiltration. Twenty patients with stage I-III breast cancer receiving neoadjuvant chemotherapy were included (participation rate: 27%). Patients were randomised into the intervention group consisting of a six-week supervised aerobic and resistance exercise program or the control group. Blood samples and tumour biopsies were collected before randomisation and after six weeks of chemotherapy. For 8 of 20 (40%) patients, we were able to obtain and analyse biopsies at diagnosis and six-week follow-up. Upon co-culture of peripheral blood mononuclear cells with K562 tumour cells, the exercise group showed increased expression of the degranulation marker CD107a on NK cells (β=1038.5, 95%CI=56.9; 2020.2, p=0.04), and a trend towards increased tumour cell lysis (β=18.8%, 95%CI=-3.9; 41.5, p=0.10) compared to the control group. In conclusion, the study design was feasible with regard to the participation rate, however, revision is needed with regard to the use of a study-related biopsy. Preliminary evidence was found that exercise during chemotherapy may enhance peripheral NK cell function. Larger studies are needed to extensively study the potential effects of exercise on immune cell function and tumour infiltration in patients with cancer.
- Open Access
- 26 June 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1212432
Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib
Immune checkpoint inhibitor therapy for cancer treatment can give rise to a variety of adverse events. Here we report a male patient with metastatic melanoma who experienced life-threatening colitis and duodenitis following treatment with ipilimumab and nivolumab. The patient did not respond to the first three lines of immunosuppressive therapy (corticosteroids, infliximab, and vedolizumab), but recovered well after administration of tofacitinib, a JAK inhibitor. Cellular and transcriptional data on colon and duodenum biopsies shows significant inflammation in the tissue, characterized by a large number of CD8 T cells and high expression of PD-L1. While cellular numbers do decrease during three lines of immunosuppressive therapy, CD8 T cells remain relatively high in the epithelium, along with PD-L1 expression in the involved tissue and expression of colitis-associated genes, indicating an ongoing colitis at that moment. Despite all immunosuppressive treatments, the patient has an ongoing tumor response with no evidence of disease. Tofacitinib might be a good candidate to consider more often for ipilimumab/nivolumab-induced colitis.
- 26 June 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1212432
Open AccessCase Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib
Immune checkpoint inhibitor therapy for cancer treatment can give rise to a variety of adverse events. Here we report a male patient with metastatic melanoma who experienced life-threatening colitis and duodenitis following treatment with ipilimumab and nivolumab. The patient did not respond to the first three lines of immunosuppressive therapy (corticosteroids, infliximab, and vedolizumab), but recovered well after administration of tofacitinib, a JAK inhibitor. Cellular and transcriptional data on colon and duodenum biopsies shows significant inflammation in the tissue, characterized by a large number of CD8 T cells and high expression of PD-L1. While cellular numbers do decrease during three lines of immunosuppressive therapy, CD8 T cells remain relatively high in the epithelium, along with PD-L1 expression in the involved tissue and expression of colitis-associated genes, indicating an ongoing colitis at that moment. Despite all immunosuppressive treatments, the patient has an ongoing tumor response with no evidence of disease. Tofacitinib might be a good candidate to consider more often for ipilimumab/nivolumab-induced colitis.
- Open Access
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study
Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a novel treatment for patients with castration-resistant prostate cancer (CRPC). Given the mode of action, patients in an earlier disease stage, such as hormone-sensitive prostate cancer (HSPC), are also likely to benefit from [177Lu]Lu-PSMA- (177Lu-PSMA) or [225Ac]Ac-PSMA-radioligand treatment (225Ac-PSMA). In this retrospective study, we analyzed the safety and efficacy of PSMA-RLT in early-stage and hormone-sensitive metastatic prostate cancer patients. Methods: A retrospective study was performed in patients who received 177Lu-PSMA and/or 225Ac-PSMA with early-stage metastatic prostate cancer. The primary outcome parameter evaluated in this study was the progression-free survival (PFS) after PSMA-RLT and toxicity according to the Common Terminology Criteria for Adverse Events. Secondary outcome parameters were prostate-specific antigen (PSA) response and the date of onset of CRPC state. Results: In total, 20 patients were included of which 18 patients received 177Lu-PSMA radioligand and two patients received tandem treatment with both 177Lu-PSMA and 225Ac-PSMA radioligands. Patients received a median of 2 treatment cycles (range 1–6) and a median activity of 6.2 GBq 177Lu-PSMA per cycle (interquartile range (IQR) 5.2–7.4 GBq). PSMA-RLT was overall well-tolerated. The most common grade 1–2 side effects were xerostomia (n = 6) and fatigue (n = 8), which were only temporarily reported. One patient that received 225Ac-PSMA developed grade 3–4 bone marrow toxicity. The median PFS was 12 months (95% confidence interval (CI), 4.09–19.9 months). Seventeen (85%) patients had a ≥50% PSA response following PSMA-RLT. One patient developed CRPC 9 months following PSMA-RLT. Conclusions: In this small cohort study, PSMA-RLT appeared safe and showed encouraging efficacy for (metastasized) early-stage and hormone-sensitive prostate cancer patients. Prospective studies are awaited and should include long-term follow-up.
Open AccessPSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study
Background: Prostate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a novel treatment for patients with castration-resistant prostate cancer (CRPC). Given the mode of action, patients in an earlier disease stage, such as hormone-sensitive prostate cancer (HSPC), are also likely to benefit from [177Lu]Lu-PSMA- (177Lu-PSMA) or [225Ac]Ac-PSMA-radioligand treatment (225Ac-PSMA). In this retrospective study, we analyzed the safety and efficacy of PSMA-RLT in early-stage and hormone-sensitive metastatic prostate cancer patients. Methods: A retrospective study was performed in patients who received 177Lu-PSMA and/or 225Ac-PSMA with early-stage metastatic prostate cancer. The primary outcome parameter evaluated in this study was the progression-free survival (PFS) after PSMA-RLT and toxicity according to the Common Terminology Criteria for Adverse Events. Secondary outcome parameters were prostate-specific antigen (PSA) response and the date of onset of CRPC state. Results: In total, 20 patients were included of which 18 patients received 177Lu-PSMA radioligand and two patients received tandem treatment with both 177Lu-PSMA and 225Ac-PSMA radioligands. Patients received a median of 2 treatment cycles (range 1–6) and a median activity of 6.2 GBq 177Lu-PSMA per cycle (interquartile range (IQR) 5.2–7.4 GBq). PSMA-RLT was overall well-tolerated. The most common grade 1–2 side effects were xerostomia (n = 6) and fatigue (n = 8), which were only temporarily reported. One patient that received 225Ac-PSMA developed grade 3–4 bone marrow toxicity. The median PFS was 12 months (95% confidence interval (CI), 4.09–19.9 months). Seventeen (85%) patients had a ≥50% PSA response following PSMA-RLT. One patient developed CRPC 9 months following PSMA-RLT. Conclusions: In this small cohort study, PSMA-RLT appeared safe and showed encouraging efficacy for (metastasized) early-stage and hormone-sensitive prostate cancer patients. Prospective studies are awaited and should include long-term follow-up.
- Open Access
- 26 April 2022
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 28 (17) , 3652-3657
Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment
The development of immunotherapy, in particular immune checkpoint inhibitors (ICI), has revolutionized cancer treatment in the past decades. However, its efficacy is still limited to subgroups of patients with cancer. Therefore, effective treatment combination strategies are needed. Here, radiotherapy is highly promising, as it can induce immunogenic cell death, triggering the release of pro-inflammatory cytokines, thereby creating an immunogenic phenotype and sensitizing tumors to ICI. Recently, targeted radionuclide therapy (TRT) has attained significant interest for cancer treatment. In this approach, a tumor-targeting radiopharmaceutical is used to specifically deliver a therapeutic radiation dose to all tumor cells, including distant metastatic lesions, while limiting radiation exposure to healthy tissue. However, fundamental differences between TRT and conventional radiotherapy make it impossible to directly extrapolate the biological effects from conventional radiotherapy to TRT. In this review, we present a comprehensive overview of studies investigating the immunomodulatory effects of TRT and the efficacy of combined TRT-ICI treatment. Preclinical studies have evaluated a variety of murine cancer models in which α- or β-emitting radionuclides were directed to a diverse set of targets. In addition, clinical trials are ongoing to assess safety and efficacy of combined TRT-ICI in patients with cancer. Taken together, research indicates that combining TRT and ICI might improve therapeutic response in patients with cancer. Future research has to disclose what the optimal conditions are in terms of dose and treatment schedule to maximize the efficacy of this combined approach.
- 26 April 2022
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 28 (17) , 3652-3657
Open AccessCombining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment
The development of immunotherapy, in particular immune checkpoint inhibitors (ICI), has revolutionized cancer treatment in the past decades. However, its efficacy is still limited to subgroups of patients with cancer. Therefore, effective treatment combination strategies are needed. Here, radiotherapy is highly promising, as it can induce immunogenic cell death, triggering the release of pro-inflammatory cytokines, thereby creating an immunogenic phenotype and sensitizing tumors to ICI. Recently, targeted radionuclide therapy (TRT) has attained significant interest for cancer treatment. In this approach, a tumor-targeting radiopharmaceutical is used to specifically deliver a therapeutic radiation dose to all tumor cells, including distant metastatic lesions, while limiting radiation exposure to healthy tissue. However, fundamental differences between TRT and conventional radiotherapy make it impossible to directly extrapolate the biological effects from conventional radiotherapy to TRT. In this review, we present a comprehensive overview of studies investigating the immunomodulatory effects of TRT and the efficacy of combined TRT-ICI treatment. Preclinical studies have evaluated a variety of murine cancer models in which α- or β-emitting radionuclides were directed to a diverse set of targets. In addition, clinical trials are ongoing to assess safety and efficacy of combined TRT-ICI in patients with cancer. Taken together, research indicates that combining TRT and ICI might improve therapeutic response in patients with cancer. Future research has to disclose what the optimal conditions are in terms of dose and treatment schedule to maximize the efficacy of this combined approach.
- Open Access
- 20 January 2022
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 63 (3) , 359-361
Toward a Better Understanding of Immune Checkpoint Inhibitor Radiolabeled PET Imaging Studies
- 20 January 2022
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 63 (3) , 359-361
Open AccessToward a Better Understanding of Immune Checkpoint Inhibitor Radiolabeled PET Imaging Studies
- Open Access
- 29 October 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
Immune checkpoint inhibitors (ICIs) have provided tremendous clinical benefit in several cancer types. However, systemic activation of the immune system also leads to several immune-related adverse events. Of these, ICI-mediated colitis (IMC) occurs frequently and is the one with the highest absolute fatality. To improve current treatment strategies, it is important to understand the cellular mechanisms that induce this form of colitis. In this review, we discuss important pathways that are altered in IMC in mouse models and in human colon biopsy samples. This reveals a complex interplay between several types of immune cells and the gut microbiome. In addition to a mechanistic understanding, patients at risk should be identifiable before ICI therapy. Here we propose to focus on T-cell subsets that interact with bacteria after inducing epithelial damage. Especially, intestinal resident immune cells are of interest. This may lead to a better understanding of IMC and provides opportunities for prevention and management.
- 29 October 2021
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 12
Open AccessMechanisms of Immune Checkpoint Inhibitor-Mediated Colitis
Immune checkpoint inhibitors (ICIs) have provided tremendous clinical benefit in several cancer types. However, systemic activation of the immune system also leads to several immune-related adverse events. Of these, ICI-mediated colitis (IMC) occurs frequently and is the one with the highest absolute fatality. To improve current treatment strategies, it is important to understand the cellular mechanisms that induce this form of colitis. In this review, we discuss important pathways that are altered in IMC in mouse models and in human colon biopsy samples. This reveals a complex interplay between several types of immune cells and the gut microbiome. In addition to a mechanistic understanding, patients at risk should be identifiable before ICI therapy. Here we propose to focus on T-cell subsets that interact with bacteria after inducing epithelial damage. Especially, intestinal resident immune cells are of interest. This may lead to a better understanding of IMC and provides opportunities for prevention and management.